ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Biomimetic Nanoplatform for Targeted Glioblastoma Therapy via Concurrently Triggering GPX4/DHODH Mediated Ferroptosis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Glioblastoma multiforme (GBM), the most aggressive and lethal type of brain cancer, is a considerable threat to human health. Conventional therapeutic modalities fail to yield satisfactory outcomes; therefore, a more effective intervention strategy is urgently required. Ferroptosis, a novel type of cell death, has potential for GBM therapy. However, its efficacy is substantially compromised by the tumor-intrinsic anti-ferroptosis defense system. Moreover, approaches that trigger ferroptosis by modulating a single target are insufficient. Thus, it is imperative to simultaneously inhibit anti-ferroptotic regulators to overcome compensatory pathways and achieve robust tumor eradication. Therefore, in the present study, a multifunctional nanoplatform, hollow mesoporous manganese dioxide (H-MnO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.